Bausch Health's shares fell nearly 9% over the past week, despite announcing a strategic expansion into new markets. This decline reflects investor skepticism about the long-term impact of recent collaborations on the company's financial health.
In the past week, Bausch Health Companies Inc. has experienced a significant downturn, with shares dropping nearly 9%. This drop follows their announcement of an expanded collaboration with YUN in Mexico and several EMEA markets, which seems insufficient to reassure investors about the company's recovery.
Investor takeaway: Long-term investors may need to rethink their outlook on Bausch Health, as recent expansions do not appear to boost immediate market confidence.
Advertisement
Bausch Health Companies Inc
BHC.TO
BHC.TO
Bausch Health Companies Inc
WealthAwesomeMarket cap
$3.06B
52W high
$11.08
52W low
$6.10
1W change
+3.68%
Beta
0.37
Analyst Price Targets
Based on analyst covering BHC · as of Sep 17, 2026
Wall Street analysts forecast BHC stock price to fall 14.2% over the next 12 months.
Consensus
Moderately BearishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$7.01
-14.2% Upside
Current Price
C$8.17
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on BHC's historical volatility
30-Day Vol
46.3%
Annualized
90-Day Vol
66.6%
Annualized
Trend (90d)
+36.5%
Annualized drift
90d Mean
C$9.31
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$8.53 | C$7.27 – C$10.01 |
| 60 trading days | C$8.91 | C$7.11 – C$11.17 |
| 90 trading days | C$9.31 | C$7.06 – C$12.27 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Bausch Health's Stock Decline: A Reflection of Market Sentiment
Bausch Health's stock has decreased nearly 9% over the past week, bringing its market cap to CA$3.18 billion. This decline, despite positive news about market expansions and new reimbursements, shows investor hesitance regarding the company's path to profitability, especially given its current forward P/E of just 1.48x.
Bull case
Potential positives for Bausch Health:
- Expanding into new markets could diversify revenue streams.
- Adding SILIQ® to Alberta's public drug plan may improve patient access and boost sales.
- Collaborations like the one with YUN could lead to innovative products that attract a wider audience.
Bear case
Risks facing Bausch Health:
- The sharp drop in share price indicates a lack of confidence in the company's recovery strategy.
- Ongoing negative earnings, shown by a TTM EPS of CA$-4.07, raise concerns about profitability.
- A high P/B ratio of 18.74x may suggest overvaluation if growth doesn't happen as expected.
Advertisement
Why Bausch Health's Expansion Isn't Enough to Boost Confidence
Despite announcing a strategic collaboration with YUN to expand into Mexico and various EMEA markets, Bausch Health's stock hasn't reacted positively. Investors seem to be weighing the potential benefits of these expansions against ongoing financial challenges, including a negative profit margin of -10.12%. The market's response suggests that while growth initiatives are important, they may not be enough to offset concerns about the company's current financial health.
Impact of Alberta's Drug Plan on Bausch Health's Future
The recent inclusion of Bausch Health's SILIQ® under Alberta's public drug plan is a significant step forward in improving access to treatment for patients with moderate to severe plaque psoriasis. However, while this could potentially increase sales, the immediate market reaction has been lukewarm. Investors may be looking for more substantial proof of how this reimbursement will translate into better financial performance, especially given the company's current EPS of CA$-4.07.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
